ClinicalTrials.gg
RecruitingNCT06915168Updated Oct 15, 2026

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

An interventional study of Informational Intervention and Survey Administration in Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2024, registered Mar 2025).
  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Michigan Rogel Cancer Center.

Planned enrollment
30th of 36
20 · median 34
Started
2024
with 4 others
No phase
18 of 48
3 open now
Registered
45th of 48
by date

Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, this one is the 30th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 with no phase, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with breast cancer
  • Currently receiving cycle three of taxane treatment
  • Approval of medical oncologist to enroll patient
  • Experiencing any CIPN based on enrollment screening question, "In the last 7 days, what was the severity of your numbness or tingling in your hands or feet at its worst? None, Mild, Moderate, Severe, Very Severe. Patient is eligible if their answer is anything except "None"
  • Access to a smartphone or similar device that can complete CIPN DecisionAid via Qualtrics while in the waiting room

Exclusion criteria

Exclusion Criteria:

  • Inability to read or speak English
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Supportive care (CIPN DecisionAid)

    Patients receive the CIPN DecisionAid on study.

    Other: Informational Intervention · Other: Survey Administration

Interventions

  • OtherInformational Intervention

    Given CIPN DecisionAid

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in decision preparedness

    Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey.

    Time frame: up to 12 weeks

Secondary outcomes

  1. Change in decision preparedness

    Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey. A secondary analysis will be conducted using linear regression adjusting for the treatment (adjuvant versus \[vs\]. metastatic, paclitaxel vs. docetaxel, weekly vs. 3-weekly) and other baseline variables (e.g., age, chemotherapy-induced peripheral neuropathy \[CIPN\] severity).

    Time frame: up to 12 weeks

  2. Change in awareness

    Will be assessed using Question #1 on the Awareness, Preparedness, and Confidence Survey.

    Time frame: up to 12 weeks

  3. Change in discussion confidence

    Will be assessed using Question #3 on the Awareness, Preparedness, and Confidence Survey.

    Time frame: up to 12 weeks

  4. Change in decision preparedness

    Will be assessed using Question #4 on the Awareness, Preparedness, and Confidence Survey.

    Time frame: up to 12 weeks

  5. Change in decision empowerment

    Will be assessed using Question #5 on the Awareness, Preparedness, and Confidence Survey.

    Time frame: up to 12 weeks

  6. Discussion satisfaction

    Will be assessed using Question #6 on the Satisfaction and Helpfulness Survey.

    Time frame: up to 12 weeks

  7. Decision satisfaction

    Will be assessed using Question #7 on the Satisfaction and Helpfulness Survey.

    Time frame: up to 12 weeks

  8. Helpfulness

    Will be assessed using Question #8 on the Satisfaction and Helpfulness Survey.

    Time frame: up to 12 weeks

  9. Taxane chemotherapy treatment decision

    Will be assessed using Question #9 on the Satisfaction and Helpfulness Survey.

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 28 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jul 2026 → Mar 2027 and completion Jul 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Apr 8, 2025
StartActual
Nov 13, 2024
Primary completionEst.
Mar 2027was Jul 2026
CompletionEst.
Mar 2027was Jul 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Mar 2027
Oct 15, 2026
Study completion
Jul 2026→Mar 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Jul 2026→Mar 2027
    Study completion Jul 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06915168
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Nov 13, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Daniel Hertz
Contact
DLHertz@med.umich.edu
734-763-0015
Daniel L Hertz
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion